Cargando…

DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice

BACKGROUND: It is unclear whether dipeptidylpeptidase-4 (DPP-4) inhibition can counteract the impairment of cognitive function and brain injury caused by transient cerebral ischemia in type 2 diabetes. The present study was undertaken to test our hypothesis that linagliptin, a DPP-4 inhibitor, admin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, MingJie, Hasegawa, Yu, Koibuchi, Nobutaka, Toyama, Kensuke, Uekawa, Ken, Nakagawa, Takashi, Lin, Bowen, Kim-Mitsuyama, Shokei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458052/ https://www.ncbi.nlm.nih.gov/pubmed/25986579 http://dx.doi.org/10.1186/s12933-015-0218-z

Ejemplares similares

DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure
por: Koibuchi, Nobutaka, et al.
Publicado: (2014)

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
por: Lin, Bowen, et al.
Publicado: (2014)

DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho−/− mice
por: Hasegawa, Yu, et al.
Publicado: (2017)

Long‐Term Renal Denervation Normalizes Disrupted Blood Pressure Circadian Rhythm and Ameliorates Cardiovascular Injury in a Rat Model of Metabolic Syndrome
por: Katayama, Tetsuji, et al.
Publicado: (2013)

Erratum: ASK1 is involved in cognitive impairment caused by long-term high-fat diet feeding in mice
por: Toyama, Kensuke, et al.
Publicado: (2015)

ASK1 is involved in cognitive impairment caused by long-term high-fat diet feeding in mice
por: Toyama, Kensuke, et al.
Publicado: (2015)

Renal Denervation Prevents Stroke and Brain Injury via Attenuation of Oxidative Stress in Hypertensive Rats
por: Nakagawa, Takashi, et al.
Publicado: (2013)

Novel Mechanism for Disrupted Circadian Blood Pressure Rhythm in a Rat Model of Metabolic Syndrome—The Critical Role of Angiotensin II
por: Sueta, Daisuke, et al.
Publicado: (2013)

High‐Fat‐Diet Intake Enhances Cerebral Amyloid Angiopathy and Cognitive Impairment in a Mouse Model of Alzheimer's Disease, Independently of Metabolic Disorders
por: Lin, Bowen, et al.
Publicado: (2016)

Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
por: Kusaka, Hiroaki, et al.
Publicado: (2016)

Detrimental Effects of Centrally Administered Angiotensin II are Enhanced in a Mouse Model of Alzheimer Disease Independently of Blood Pressure
por: Takane, Koki, et al.
Publicado: (2017)

Calcium Channel Blockers, More than Diuretics, Enhance Vascular Protective Effects of Angiotensin Receptor Blockers in Salt-Loaded Hypertensive Rats
por: Yamamoto, Eiichiro, et al.
Publicado: (2012)

Correction: Calcium Channel Blockers, More than Diuretics, Enhance Vascular Protective Effects of Angiotensin Receptor Blockers in Salt-Loaded Hypertensive Rats
por: Yamamoto, Eiichiro, et al.
Publicado: (2013)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy
por: Dietrich, Nadine, et al.
Publicado: (2016)

Linagliptin Ameliorates Methylglyoxal-Induced Peritoneal Fibrosis in Mice
por: Nagai, Takuo, et al.
Publicado: (2016)

DPP-4 Inhibitor Linagliptin Ameliorates Oxidized LDL-Induced THP-1 Macrophage Foam Cell Formation and Inflammation
por: Wang, Haoran, et al.
Publicado: (2020)

The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride
por: Darsalia, Vladimer, et al.
Publicado: (2013)

DPP‐4 Inhibitor Linagliptin Attenuates Aβ‐induced Cytotoxicity through Activation of AMPK in Neuronal Cells
por: Kornelius, Edy, et al.
Publicado: (2015)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

Neuroprotective Properties of Linagliptin: Focus on Biochemical Mechanisms in Cerebral Ischemia, Vascular Dysfunction and Certain Neurodegenerative Diseases
por: Wiciński, Michał, et al.
Publicado: (2019)

Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin
por: Lietzau, Grazyna, et al.
Publicado: (2018)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

Study Protocol for the Initial Choice of DPP-4 Inhibitor in Japanese Patients with Type 2 diabetes Mellitus: Effect of Linagliptin on QOL (INTEL-QOL) Trial
por: Mita, Tomoya, et al.
Publicado: (2018)

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
por: Korbut, Anton I., et al.
Publicado: (2020)

The clinical application of linagliptin in Asians
por: Cao, Chu-qing, et al.
Publicado: (2015)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis
por: Shiheido-Watanabe, Yuka, et al.
Publicado: (2021)

Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis
por: Adhikari, Juthi, et al.
Publicado: (2023)

Targeting DPP4-RBD interactions by sitagliptin and linagliptin delivers a potential host-directed therapy against pan-SARS-CoV-2 infections
por: Mani, Shailendra, et al.
Publicado: (2023)

Combination of Linagliptin and Empagliflozin Preserves Cardiac Systolic Function in an Ischemia-Reperfusion Injury Mice With Diabetes Mellitus
por: Ideishi, Akihito, et al.
Publicado: (2021)

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
por: Jojima, Teruo, et al.
Publicado: (2016)

Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice
por: Aroor, Annayya R., et al.
Publicado: (2017)

Minocycline Ameliorates Depressive-Like Behavior and Demyelination Induced by Transient Global Cerebral Ischemia by Inhibiting Microglial Activation
por: Du, Bingying, et al.
Publicado: (2019)

Incorrect description of mode of excretion of linagliptin
por: Woerle, Hans-Juergen, et al.
Publicado: (2010)

Acute Kidney Injury Associated with Linagliptin
por: Nandikanti, Deepak K., et al.
Publicado: (2016)

Linagliptin-Associated Alopecia and Bullous Pemphigoid
por: Someili, Ali, et al.
Publicado: (2019)

Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design
por: Jadhav, Sushant B., et al.
Publicado: (2016)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice
por: Nakaoku, Yuriko, et al.
Publicado: (2019)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model
por: Wang, Shen-Chih, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i1ur59k7cc5dli643k13ghtrv6